ATE309382T1 - Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse - Google Patents

Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse

Info

Publication number
ATE309382T1
ATE309382T1 AT97914375T AT97914375T ATE309382T1 AT E309382 T1 ATE309382 T1 AT E309382T1 AT 97914375 T AT97914375 T AT 97914375T AT 97914375 T AT97914375 T AT 97914375T AT E309382 T1 ATE309382 T1 AT E309382T1
Authority
AT
Austria
Prior art keywords
gene therapy
recombinant adenovirus
human cancers
adenovirus vectors
disclosed
Prior art date
Application number
AT97914375T
Other languages
English (en)
Inventor
Falleur Boon
Marie-Therese Duffour
Hedi Haddada
Christophe Lurquin
Michel Perricaudet
Catherine Uyttenhoveghesquiere
Guy Warnier
Original Assignee
Aventis Pharma Sa
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Ludwig Inst Cancer Res filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE309382T1 publication Critical patent/ATE309382T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT97914375T 1996-03-14 1997-03-12 Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse ATE309382T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9603207A FR2746110B1 (fr) 1996-03-14 1996-03-14 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
PCT/FR1997/000435 WO1997034009A1 (fr) 1996-03-14 1997-03-12 Vecteurs adenoviraux recombinants pour la therapie genique des tumeurs humaines

Publications (1)

Publication Number Publication Date
ATE309382T1 true ATE309382T1 (de) 2005-11-15

Family

ID=9490181

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97914375T ATE309382T1 (de) 1996-03-14 1997-03-12 Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse

Country Status (19)

Country Link
US (1) US20030082150A1 (de)
EP (1) EP0889969B1 (de)
JP (1) JP2000507229A (de)
KR (1) KR19990087718A (de)
CN (1) CN1218512A (de)
AT (1) ATE309382T1 (de)
AU (1) AU732288B2 (de)
BR (1) BR9707994A (de)
CA (1) CA2248612A1 (de)
CZ (1) CZ295967B6 (de)
DE (1) DE69734574T2 (de)
DK (1) DK0889969T3 (de)
ES (1) ES2252779T3 (de)
FR (1) FR2746110B1 (de)
HU (1) HUP9902150A3 (de)
IL (1) IL126152A0 (de)
NO (1) NO984052D0 (de)
SK (1) SK124698A3 (de)
WO (1) WO1997034009A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4668797A (en) * 1996-10-07 1998-05-05 Ludwig Institute For Cancer Research Replication-defective adenoviruses for cancer immunotherapy
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
ATE346925T1 (de) * 2000-05-10 2006-12-15 Sanofi Pasteur Ltd Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
JP5089847B2 (ja) * 2001-03-27 2012-12-05 ニューヨーク・ユニバーシティ アルファウイルスに基づく高親和性ラミニン受容体標的化ベクターを用いた腫瘍の治療
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
EP1497412A4 (de) * 2002-04-30 2006-11-22 Avior Therapeutics Inc Adenovirusvektoren zur immuntherapie
CN1327000C (zh) * 2002-09-06 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
PL3198009T3 (pl) 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
CN1115414C (zh) * 1993-07-13 2003-07-23 罗纳-布朗克罗莱尔股份有限公司 用于基因治疗的病毒载体

Also Published As

Publication number Publication date
CN1218512A (zh) 1999-06-02
SK124698A3 (en) 1999-05-07
DE69734574T2 (de) 2006-07-13
BR9707994A (pt) 1999-07-27
JP2000507229A (ja) 2000-06-13
NO984052L (no) 1998-09-03
KR19990087718A (ko) 1999-12-27
HUP9902150A3 (en) 2000-12-28
CZ291598A3 (cs) 1998-12-16
AU2164197A (en) 1997-10-01
CZ295967B6 (cs) 2005-12-14
ES2252779T3 (es) 2006-05-16
CA2248612A1 (fr) 1997-09-18
EP0889969B1 (de) 2005-11-09
IL126152A0 (en) 1999-05-09
AU732288B2 (en) 2001-04-12
NO984052D0 (no) 1998-09-03
EP0889969A1 (de) 1999-01-13
FR2746110B1 (fr) 1998-04-17
DE69734574D1 (de) 2005-12-15
WO1997034009A1 (fr) 1997-09-18
FR2746110A1 (fr) 1997-09-19
HUP9902150A2 (hu) 1999-11-29
US20030082150A1 (en) 2003-05-01
DK0889969T3 (da) 2006-03-27

Similar Documents

Publication Publication Date Title
DE69734574D1 (de) Rekombinante adenovirenvektoren zur gentherapie der menschlichen krebse
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
IL145731A0 (en) A polypetide containing an immunogenic portion of a breast tumor protein and pharmaceutical compositions containing the same
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
HUP0203035A2 (hu) Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások
MXPA03001389A (es) Composiciones y metodos para la terapia y diagnostico de malignidades asociadas con her-2/neu.
NO20004631D0 (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
IT1298487B1 (it) Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
YU65103A (sh) Peg-konjugati hgf-nk4
TR199901190T2 (xx) Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler.
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
AR019844A1 (es) Polipeptidos composicion farmaceutica, procedimiento para preparar dicha composicion metodo para tratar y prevenir el cancer y metodo para inhibir elcrecimiento de celulas tumorales
ATE514780T1 (de) Zusammensetzungen für die therapie und diagnose von brustkrebs und verwendung davon
DK1007717T3 (da) Metoder og sammensætninger til cancerterapi under anvendelse af gener, der koder for interferon-beta
NO991653D0 (no) Immunogenisk tumor frigjorte partikler (TLP)-blanding

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0889969

Country of ref document: EP

REN Ceased due to non-payment of the annual fee